Indian pharma stocks are rebounding, driven by domestic investors after a period of Foreign Institutional Investor (FII) selling pressure. Uncertainty surrounding potential US tariffs, fueled by Trump’s statements and delays in the Bilateral Trade Agreement (BTA), had initially impacted the sector. While FIIs remain cautious, positive earnings reports and the defensive nature of domestic-oriented pharma businesses are attracting DII interest.
Willing to pay extra to build resilience in our supply chains: Piyush Goyal
India is actively addressing supply chain vulnerabilities across all sectors, willing to invest more to build resilience. The government’s ‘Atmanirbhar Bharat’ initiative, coupled with infrastructure
October 22, 2025